1-(2-氯苯基)戊烷-1,4-二酮 | 153686-97-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氯苯基)戊烷-1,4-二酮
• 英文名称: 1-(2-chlorophenyl)pentane-1,4-dione
• CAS: 153686-97-6
• 化学式: C₁₁H₁₁ClO₂
• 分子量: 210.66
• InChiKey: ALQDACRHBJXPQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-氯苯基)戊烷-1,4-二酮 在 溶剂黄146 作用下， 以 水 、 乙腈 为溶剂， 反应 3.0h， 生成 1-[[5-(2-Chlorophenyl)-2-methyl-1-phenyl-pyrrol-3-yl]methyl]-4-methyl-piperazine
  参考文献：
  名称：

  Antimycobacterial compounds. New pyrrole derivatives of BM212

  摘要：

  We have identified BM212 as a lead compound among a series of pyrrole derivatives with good in vitro activity against mycobacteria and candidae. First studies led us to synthesize some pyrrole compounds in which the thiomorpholine fragment was present. Some compounds revealed very active and these findings prompted us to prepare new pyrrole derivatives 2-15 in the hope of increasing the activity. The microbiological data showed interesting in vitro activity against Mycobacterium tuberculosis and atypical mycobacteria. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.037
• 作为产物：
  描述：

  2-氯苯甲醛 、 丁烯酮 在 sodium acetate 、 3-苄基羟乙基甲基噻唑氯化锂 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(2-氯苯基)戊烷-1,4-二酮
  参考文献：
  名称：

  具有潜在抗抑郁作用的 SERT 抑制剂 1-(1,5-双(4-取代苯基)-2-甲基-1H-吡咯-3-基)-N-甲基甲胺的设计、合成和评价

  摘要：

  BM212 是一种有效的抗结核药物，其药效特征与抗抑郁药物舍曲林相似。对 BM212 上的 DrugBank 数据库进行基于形状的虚拟筛选，鉴定出了几种具有明显 Tanimoto 评分的 CNS 药物。对接模拟还确定了 BM212 对血清素再摄取转运蛋白 (SERT) 的选择性，对接分数为 -6.51 kcal mol -1。基于舍曲林和其他抗抑郁药物的SAR数据，我们设计、合成并筛选了12个1-(1,5-双(4-取代苯基)-2-甲基-1H-吡咯-3-基) -N -甲基甲胺（SA-1 至 SA-12）用于体外SERT 抑制和体内抗抑郁活性。使用血小板模型筛选化合物的体外5HT 再摄取抑制作用。在筛选的化合物中，(1-(1,5-双(4-氯苯基)-2-甲基-1H-吡咯-3-基) -N-甲基甲胺)表现出与标准药物舍曲林（吸光度 0.22）。BM212 对 5-HT 摄取有影响，尽管与标准品相比较弱（吸光度

  DOI：

  10.1039/d2md00243d

文献信息

• Copper-Catalyzed Decarboxylative Oxyalkylation of Alkynyl Carboxylic Acids: Synthesis of γ-Diketones and γ-Ketonitriles
  作者：Yi Li、Jia-Qi Shang、Xiang-Xiang Wang、Wen-Jin Xia、Tao Yang、Yangchun Xin、Ya-Min Li

  DOI：10.1021/acs.orglett.9b00520

  日期：2019.4.5

  A novel copper-catalyzed decarboxylative oxyalkylation of alkynyl carboxylic acids with ketones and alkylnitriles via direct C(sp3)–H bond functionalization to construct new C–C bonds and C–O double bonds was developed. This transformation is featured by wide functional group compatibility and the use of readily available reagents, thus affording a general approach to γ-diketones and γ-ketonitriles

  通过直接的C（sp 3）-H键官能化来构建新的C-C键和C-O双键的新型铜催化的炔基羧酸与酮和烷基腈的脱羧氧化烷基化反应得到了发展。这种转变的特征是广泛的官能团相容性和易于使用的试剂的使用，从而为γ-二酮和γ-酮腈提供了一种通用方法。提出了一种可能的机制。
• Process for the preparation of ketones
  申请人：Bayer Aktiengesellschaft

  公开号：US04035395A1

  公开（公告）日：1977-07-12

  The invention concerns a new process for the preparation of ketones; according to this process ketones are prepared from aldehydes and unsaturated compounds in the presence of bases using quaternary ammonium salts as catalysts.

  这项发明涉及一种新的酮类制备过程；根据这个过程，在碱的存在下，使用季铵盐作为催化剂，从醛和不饱和化合物制备酮。
• [EN] PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS<br/>[FR] DERIVES DE PYRROLE SERVANT DE COMPOSES ANTI-MYCOBACTERIENS
  申请人：LUPIN LTD

  公开号：WO2004026828A1

  公开（公告）日：2004-04-01

  Novel pyrrole derivatives of formula (I), and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

  公式(I)的新型吡咯衍生物及其药学上可接受的酸盐，在临床上对结核分枝杆菌的敏感和耐药菌株具有优越的抗结核活性，且与已知化合物相比具有较低的毒性。利用公式(I)的新型化合物治疗潜伏性结核病，包括多药耐药结核病（MDR TB）。制备新型化合物的方法，含有新型化合物的药物组合物以及通过给予公式(I)化合物治疗MDR TB的方法。
• Antimycobacterial pharmaceutical composition
  申请人：Arora Kumar Sudershan

  公开号：US20050256128A1

  公开（公告）日：2005-11-17

  An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.

  描述了一种用于治疗结核病的抗分枝杆菌联合组合物和组合物。所使用的化合物为式（I）的N-(3-[[4-(3-三氟甲基苯基)哌嗪基]甲基]-2-甲基-5-苯基-吡咯基)-4-吡啶基甲酰胺，或其药学上可接受的非毒性盐，以及一种或多种一线抗结核药物的数量。
• Pyrrole derivatives as antimycobacterial compounds
  申请人：Arora Kumar Sudershan

  公开号：US20050107370A1

  公开（公告）日：2005-05-19

  Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

  式(I)的新型吡咯衍生物及其药学上可接受的酸盐，具有优异的抗结核杆菌活性，对临床敏感和耐药菌株的Mycobacterium tuberculosis均有效，并且与已知化合物相比具有较小的毒性。使用式(I)的新型化合物治疗潜伏性结核病，包括多重耐药结核病（MDR TB）。制备新型化合物的方法，含有新型化合物的制药组合物以及通过给予式(I)化合物治疗MDR TB的方法。